Orders by weight:
Contains a disruption of the p53 tumor suppressor gene, the most commonly mutated gene in human cancers
Useful for studying p53 gene function or screening potential cancer intervention therapies
TSG-p53® (N5) is the only TSG-p53® mouse validated for use in evaluation studies required by the FDA as an alternative to the 2-year carcinogenicity bioassay
Heterozygous TSG-p53® mice carry one normal p53 allele and have a low rate of spontaneous tumor development
Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
Genetic Background: C57BL/6 Background
The TSG-p53® mouse was developed in the laboratory of Lawrence A. Donehower and Allan Bradley at the Baylor College of Medicine. The model was created by targeting the Trp53 gene in AB1 ES cells and injecting the targeted cells into C57BL/6 blastocysts. Resultant chimeras were backcrossed to C57BL/6J for two generations (N2). Taconic received stock in 1991. The mice were backcrossed to N3 for caesarean derivation and to N4 immediately after derivation. The homozygous colony was maintained at N4 through mating of heterozygous females with homozygous males. The heterozygous colony was maintained at N5 through mating of N4 male homozygotes to C57BL/6NTac females.
Production of TSG-p53N5 mice:
TSG-p53 N5 mice are produced using IVF. Wild type C57BL/6 oocytes are fertilized with cryopreserved sperm from homozygous TSG-p53 N4 males. The resulting offspring are heterozygous for the gene of interest. Cohorts of 10-20 heterozygous offspring, mixed sex, 8-9 weeks of age, can be available for shipment to the client approximately 14-16 wks from placing the order. Larger cohorts of heterozygous offspring can be made available upon request.
Please contact us
for placing your order.
Genetics: Wild type for Nnt mutation
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr, Butel JS, Bradley A. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature, 356:215-221